UNI HEALTH (02211): Intends to sell 43.78% equity of Jilin Jintian Dajiankang Group Capsule Co., Ltd. for a total of 43 million yuan.

UNI HEALTH (02211) announced that on November 19, 2024, the seller (indirect wholly-owned subsidiary Heilongjiang Jintian Aixin Pharmaceutical Distribution Co., Ltd.) intends to sell 43.78% equity of the target company (Jilin Jintian Big Health Group Capsule Co., Ltd.) to the buyer (Huang Yanling) for RMB 43 million, subject to the terms of the equity transfer agreement. After the completion of the sale, the company will no longer hold any shares in the target company. The target company's business includes the production, sales, and research and development of hollow capsules, making it a leading capsule production company in Northeast China. The group is mainly engaged in the distribution and retail of pharmaceuticals and other medical products in Northeast China. To strengthen the group's cash flow situation to meet the group's funding needs, the board of directors has decided to proceed with the sale. In addition, the company believes that through the sale, it will be able to optimize and adjust its asset structure to increase asset liquidity, improve the efficiency of asset utilization, and derive certain benefits from it.